Prostate cancer polygenic risk score and prediction of lethal prostate cancer

• Published in: NPJ precision oncology Vol. 6; no. 1; p. 25
• Main Authors: Klein, Robert J., Vertosick, Emily, Sjoberg, Dan, Ulmert, David, Rönn, Ann-Charlotte, Häggström, Christel, Thysell, Elin, Hallmans, Göran, Dahlin, Anders, Stattin, Pär, Melander, Olle, Vickers, Andrew, Lilja, Hans
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 08.04.2022; Nature Publishing Group; Nature Portfolio
• Subjects: 692/420/2489/144; 692/53/2422; 692/699/67/589/466; Cancer and Oncology; Cancer och onkologi; Cancer Research; Clinical Medicine; Gene Therapy; Genotype & phenotype; Health risks; Human Genetics; Internal Medicine; Klinisk medicin; Medical and Health Sciences; Medical screening; Medicin och hälsovetenskap; Medicine; Medicine & Public Health; Metastasis; Oncology; Precision medicine; Prostate cancer
• ISSN: 2397-768X; 2397-768X
• DOI: 10.1038/s41698-022-00266-8

Polygenic risk scores (PRS) for prostate cancer incidence have been proposed to optimize prostate cancer screening. Prediction of lethal prostate cancer is key to any stratified screening program to avoid excessive overdiagnosis. Herein, PRS for incident prostate cancer was evaluated in two population-based cohorts of unscreened middle-aged men linked to cancer and death registries: the Västerbotten Intervention Project (VIP) and the Malmö Diet and Cancer study (MDC). SNP genotypes were measured by genome-wide SNP genotyping by array followed by imputation or genotyping of selected SNPs using mass spectrometry. The ability of PRS to predict lethal prostate cancer was compared to PSA and a commercialized pre-specified model based on four kallikrein markers. The PRS was associated with incident prostate cancer, replicating previously reported relative risks, and was also associated with prostate cancer death. However, unlike PSA, the PRS did not show stronger association with lethal disease: the hazard ratio for prostate cancer incidence vs. prostate cancer metastasis and death was 1.69 vs. 1.65 in VIP and 1.25 vs. 1.25 in MDC. PSA was a much stronger predictor of prostate cancer metastasis or death with an area-under-the-curve of 0.78 versus 0.63 for the PRS. Importantly, addition of PRS to PSA did not contribute additional risk stratification for lethal prostate cancer. We have shown that a PRS that predicts prostate cancer incidence does not have utility above and beyond that of PSA measured at baseline when applied to the clinically relevant endpoint of prostate cancer death. These findings have implications for public health policies for delivery of prostate cancer screening. Focusing polygenic risk scores on clinically significant endpoints such as prostate cancer metastasis or death would likely improve clinical utility.